Friday, February 26, 2021 11:26:39 AM
But, really, not only do I think I'm right, I think it makes sense that things are this way.
The market is finite. The worth of therapeutics, whether mAbs, molecules, etc., and regardless of the various methods of action, will all have value depending on how much market share they can obtain. I think the Covid stocks I have will all gain a piece of that action, if they are validated.
Assuming they all obtain about equal amounts of the market, share price will be justifiably established, and HGEN will show higher EPS due to having far fewer shareholders than these other companies. Of course, if lenz proves much more effective, that will be a big determinant of EPS, too. I still have 66% of my account in HGEN, and I am just riding it out until each of the companies I have complete their trials.
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM